Frank Takkinen Analyst Performance

Senior Research Analyst at Lake Street Capital

Frank Takkinen is a stock analyst at Lake Street Capital focused in the medical sector, covering 14 publicly traded companies. Over the past year, Frank Takkinen has issued 16 stock ratings, including buy and hold recommendations. While full access to Frank Takkinen's proprietary MarketBeat Analyst Ranking is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Frank Takkinen's coverage history, rating activity, and performance tendencies — helping individual investors make more informed trading decisions.

Analyst Ranking: Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating MarketBeat
Average Return: 00.00% 12-Month ROI
Success Rate: 00.00% Profitable Ratings
Total Ratings: 19 Last 5 Years
Buy Recommendations: 94.74% 18 Buy Ratings
Companies Covered: 14 Unique Companies

Ratings Distribution

Rating	Percentage	Count
Strong Buy	0.0%	0 ratings
Buy	94.7%	18 ratings
Hold	5.3%	1 ratings
Sell	0.0%	0 ratings

Out of 19 total stock ratings issued by Frank Takkinen at Lake Street Capital, the majority (94.7%) have been Buy recommendations, followed by 5.3% Hold.

Best & Worst Calls

Best Call
000.0%
INSP
Aug 2020
Subscribe to MarketBeat All Access to get analyst recommendation ROI.
Worst Call
000.0%
OSUR
Sep 2021
Subscribe to MarketBeat All Access to get analyst recommendation ROI.

Exchange Coverage

Exchange	Percentage	Count
NASDAQ	92.9% of companies on NASDAQ	13 companies
NYSE	7.1% of companies on NYSE	1 company

Frank Takkinen, an analyst at Lake Street Capital, currently covers 14 companies listed on NASDAQ and NYSE, with the majority traded on NASDAQ.

Coverage Focus

Sector Icon	Sector	Percentage
	Medical 13 companies	92.9%
	Computer and Technology 1 company	7.1%

Frank Takkinen of Lake Street Capital specializes in stock coverage within the Medical sector, with additional focus on Computer and Technology companies.

Coverage Industries

Industry	Percentage
MED INSTRUMENTS 7 companies	50.0%
MEDICAL INFO SYS 3 companies	21.4%
MED - BIOMED/GENE 1 company	7.1%
MED - DRUGS 1 company	7.1%
INTERNET SOFTWARE 1 company	7.1%
MED PRODUCTS 1 company	7.1%

Timeframe

Start Date

End Date

Rating

12-Month ROIAll ROI

Export to Excel

Company	Report Date	Action	Report Date Price	12-Month Price Target	Rating
ELUT Elutia	9/10/2025	Lower Price Target	$1.35	$6.00	Buy
HYPR Hyperfine	8/14/2025	Boost Price Target	$1.47	$2.00	Buy
SGHT Sight Sciences	8/8/2025	Upgrade	$3.55	$5.00	Buy
INSP Inspire Medical Systems	8/5/2025	Set Price Target	$77.62	$150.00	Buy
LUNG Pulmonx	7/31/2025	Lower Price Target	$1.84	$8.00	Buy
ANGO AngioDynamics	7/16/2025	Initiated Coverage	$8.66	$24.00	Buy
ELUT Elutia	5/9/2025	Lower Price Target	$1.99	$8.00	Buy
NOTV Inotiv	5/8/2025	Lower Price Target	$2.33	$5.00	Buy
CVRX CVRx	4/8/2025	Lower Price Target	$6.20	$14.00	Buy
HYPR Hyperfine	3/24/2025	Initiated Coverage	$0.82	$1.50	Buy
LNSR LENSAR	3/24/2025	Reiterated Rating	$14.40	$15.00	Hold
AXGN AxoGen	3/17/2025	Initiated Coverage	$17.25	$30.00	Buy
LNSR LENSAR	2/28/2025	Boost Price Target	$12.18	$16.00	Buy
CLBT Cellebrite DI	2/14/2025	Boost Price Target	$20.43	$26.00	Buy
CLPT ClearPoint Neuro	1/21/2025	Boost Price Target	$17.60	$30.00	Buy
KRMD KORU Medical Systems	1/14/2025	Boost Price Target	$3.88	$5.00	Buy

Stock Forecasts and Research Tools

Today's Ratings

Top-Rated Stocks

More Ratings Tools

Price Forecasts for Popular Stocks

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.